Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that ...

Czech National Bank increased its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 7.3% during the 4th quarter, according to the company in its most recent 13F filing with the ...

Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Thermo Fisher Scientific should be safe. RFK Jr. may disrupt Big Pharma, but he’s unlikely to cause research to completely ...